| Columbus Primary Care Internal Medicine Pc | |
|
1041 Talbotton Rd Columbus GA 31904-8745 | |
| (706) 660-8825 | |
| (706) 660-8897 |
| Full Name | Columbus Primary Care Internal Medicine Pc |
|---|---|
| Speciality | Internal Medicine |
| Location | 1041 Talbotton Rd, Columbus, Georgia |
| Authorized Official Name and Position | Edet O Bassey (CEO PRESIDENT) |
| Authorized Official Contact | 7066608825 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Columbus Primary Care Internal Medicine Pc Po Box 2746 Columbus GA 31902-2746 Ph: (706) 660-8825 | Columbus Primary Care Internal Medicine Pc 1041 Talbotton Rd Columbus GA 31904-8745 Ph: (706) 660-8825 |
| NPI Number | 1063566909 |
|---|---|
| Provider Enumeration Date | 01/22/2007 |
| Last Update Date | 05/11/2010 |
| Medicare PECOS PAC ID | 8022002757 |
|---|---|
| Medicare Enrollment ID | O20040414000416 |
News Archive
The coronavirus disease (COVID-19) has ravaged across the globe, infecting a staggering 3.5 million people, and taking over 251,000 lives. One of the most significant concerns in this global pandemic is the possibility of reinfection as previous reports in South Korea and Japan show people testing positive with the coronavirus again.
One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.
Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.
Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063566909 | NPI | - | NPPES |
| 000807881C | Medicaid | GA | |
| 00807881C | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 044408 (Georgia) | Primary |
| Provider Name | Edet O Bassey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1336123181 PECOS PAC ID: 4082712757 Enrollment ID: I20080304000072 |
News Archive
The coronavirus disease (COVID-19) has ravaged across the globe, infecting a staggering 3.5 million people, and taking over 251,000 lives. One of the most significant concerns in this global pandemic is the possibility of reinfection as previous reports in South Korea and Japan show people testing positive with the coronavirus again.
One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.
Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.
Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).
› Verified 9 days ago
News Archive
The coronavirus disease (COVID-19) has ravaged across the globe, infecting a staggering 3.5 million people, and taking over 251,000 lives. One of the most significant concerns in this global pandemic is the possibility of reinfection as previous reports in South Korea and Japan show people testing positive with the coronavirus again.
One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours at the Medical University of Vienna and Harvard Medical School, USA, have just been published. They show that the TRAIL protein opens up the prospect to a more accurate prediction of the disease's course, as well as the opportunity to identify a new intervention point for innovative therapies in advanced prostate cancer.
Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.
Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).
› Verified 9 days ago
Family Wellcare Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4215 Woodruff Rd, Columbus, GA 31904 Phone: 706-653-6080 Fax: 706-653-6052 | |
One On One Staffing &wellness Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1315 Delauney Ave Ste 201-a, Columbus, GA 31901 Phone: 334-655-0315 | |
Gabiana Medical Offices Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 Center St, 201 Professional Tower, Columbus, GA 31901 Phone: 706-323-4747 Fax: 706-660-0676 | |
Mac - Macon Road Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3465 Macon Rd Ste D, Columbus, GA 31907 Phone: 706-243-3051 | |
Unitehere Union Health & Wellness Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1110 Farr Rd Ste C, Columbus, GA 31907 Phone: 706-683-0909 Fax: 706-683-9757 | |
Novela Health Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6901 Ray Wright Way Ste D, Columbus, GA 31909 Phone: 404-543-9924 |